» Articles » PMID: 31463641

An Assessment of the Relationship Between the Expression of CCR7/CCL19 Axis and Selected Regulatory MiRNAs in Non-small Cell Lung Cancer

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2019 Aug 30
PMID 31463641
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

CC chemokine receptor type 7 (CCR7) and its ligands has been implicated in the occurrence and progression of NSCLC. Previous studies have revealed that the diagnostic value of CCR7/CCL19 axis in lung tumorigenesis remains controversial. The present study evaluates the relationship between the mRNA expression of CCR7/CCL19 axis and selected regulatory miRNAs in NSCLC patients. It analyzes the expression level of CCR7 mRNA and its ligand in tumor tissue in relation to expression level of two miRNAs: miR let-7a and miR-335, as transcriptional regulators of study genes. Twenty-seven patients (n = 27) were enrolled. The expression of the studied genes and miRNAs was evaluated by qPCR. Tumour tissue fragments, adjacent macroscopically-unchanged lung tissue (control) and patient serum were used as biological material for study. Elevated expression of CCR7 and CCL19 mRNA was observed in patients with metastasis to lymph nodes. We noticed upregulated miR-335 expression and downregulated miR let-7a expression in patient serum with regard to AJCC tumor staging. Higher miR-335 expression and lower miR let-7a expression level was observed in patients with metastasis to lymph node. The presence of changes observed in the expression level of miR-335 and miR let-7a in the serum of NSCLC patients in relation to lymph node metastases and tumor stage may serve as a non-invasive molecular biomarker of tumor progression; however, this observation requires further investigation.

Citing Articles

Construction of ceRNA prognostic model based on the CCR7/CCL19 chemokine axis as a biomarker in breast cancer.

Ma R, Guan X, Teng N, Du Y, Ou S, Li X BMC Med Genomics. 2023; 16(1):254.

PMID: 37864213 PMC: 10590005. DOI: 10.1186/s12920-023-01683-9.


Panel of miR-150 and linc00673, regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer.

Baran K, Kordiak J, Jablonski S, Brzezianska-Lasota E Sci Rep. 2023; 13(1):9642.

PMID: 37316552 PMC: 10267173. DOI: 10.1038/s41598-023-36485-7.


CCL19 has potential to be a potential prognostic biomarker and a modulator of tumor immune microenvironment (TIME) of breast cancer: a comprehensive analysis based on TCGA database.

Wang J, Qin D, Ye L, Wan L, Wang F, Yang Y Aging (Albany NY). 2022; 14(9):4158-4175.

PMID: 35550569 PMC: 9134962. DOI: 10.18632/aging.204081.


Identification of CCL19 as a Novel Immune-Related Biomarker in Diabetic Nephropathy.

Chen H, Zhang Z, Zhou L, Cai T, Liu B, Wang L Front Genet. 2022; 13:830437.

PMID: 35222545 PMC: 8864156. DOI: 10.3389/fgene.2022.830437.


C-C Chemokine Receptor 7 in Cancer.

Bill C, Allen C, Vines C Cells. 2022; 11(4).

PMID: 35203305 PMC: 8870371. DOI: 10.3390/cells11040656.


References
1.
Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E . CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999; 99(1):23-33. DOI: 10.1016/s0092-8674(00)80059-8. View

2.
Takanami I . Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003; 105(2):186-9. DOI: 10.1002/ijc.11063. View

3.
He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

4.
Qin X, Xu H, Gong W, Deng W . The Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer. Front Oncol. 2015; 4:357. PMC: 4283433. DOI: 10.3389/fonc.2014.00357. View

5.
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek Jr E . The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 2012; 4(4):128-34. PMC: 3351680. DOI: 10.4329/wjr.v4.i4.128. View